RESEARCH PAPER

# Ai-Driven Polypharmacology: Designing Multi-Target Drugs for Complex Diseases

**Shahab Saquib[1], Alok Kumar[2], Vijesh Kumar Patel[3], Md Shahid Ahmad[4], Ravi Kumar[5], Rajiv Kumar Ranjan[6]**

[1] Assistant Professor, Department of Computer Science and Engineering, Bakhtiyarpur College of Engineering, Bakhtiyarpur, Patna, Bihar - 803212, Under Department of Science, Technology and Technical Education, Government of Bihar. Email: saquib.zhcet@gmail.com

[2] Assistant Professor, Department of Computer Science and Engineering, Bakhtiyarpur College of Engineering, Bakhtiyarpur, Patna, Bihar - 803212, Under Department of Science, Technology and Technical Education, Government of Bihar. Email: alokalok005@gmail.com

[3] Assistant Professor, Department of Computer Science and Engineering, Government Engineering College, Bhojpur, Arrah, Bihar - 802301, Under Department of Science, Technology and Technical Education, Government of Bihar. Email: vijeshkumarpatel4@gmail.com

[4] Assistant Professor, Department of Computer Science and Engineering, Rashtrakavi Ramdhari Singh Dinkar College of Engineering, Begusarai, Bihar - 851134, Under Department of Science, Technology and Technical Education, Government of Bihar. Email: md.shahid.md@gmail.com

[5] Assistant Professor, Department of Computer Science and Engineering, Rashtrakavi Ramdhari Singh Dinkar College of Engineering, Begusarai, Bihar - 851134, Under Department of Science, Technology and Technical Education, Government of Bihar. Email: ravikmr.04@gmail.com

[6] Assistant Professor, Department of Computer Science and Engineering, Rashtrakavi Ramdhari Singh Dinkar College of Engineering, Begusarai, Bihar - 851134, Under Department of Science, Technology and Technical Education, Government of Bihar. Email: rajivkr1234@gmail.com

**Received:** 20th Feb, 2026 | **Revised:** 4th Mar, 2026 | **Accepted:** 25th Mar, 2026 | **Available Online:** 10th Apr, 2026

**ABSTRACT**

Contemporary pharmaceutical research faces significant limitations with single-target drug paradigms, particularly for multifactorial diseases such as cancer, neurodegeneration, and metabolic disorders. Polypharmacology—the deliberate design of molecules that modulate multiple disease-relevant biological targets simultaneously—offers a compelling alternative to conventional mono-target strategies. This paper investigates the convergence of artificial intelligence (AI) with polypharmacological drug design, systematically reviewing how deep learning, graph neural networks (GNNs), generative adversarial networks (GANs), and transformer-based molecular architectures are reshaping the discovery pipeline. We discuss the mechanistic basis of multi-target engagement, prominent computational frameworks for network pharmacology and target identification, and landmark AI-designed multi-target candidates across oncology, neurology, and inflammatory diseases. Benchmark comparisons reveal that transformer-based models achieve AUC-ROC scores exceeding 0.97 for multi-target affinity prediction, substantially outperforming classical machine learning baselines. We also address persistent challenges including polypharmacology selectivity, off-target toxicity prediction, and translational validation. Our analysis underscores that AI-driven polypharmacology is transitioning from a conceptual paradigm to a practical drug discovery accelerator with near-term clinical implications.

**Keywords:** Polypharmacology, Multi-Target Drug Design, Artificial Intelligence, Deep Learning, Graph Neural Networks, Network Pharmacology, Drug Discovery, Cancer, Neurodegeneration.

**How to cite this article:** Saquib S, Kumar A, Patel VK, Ahmad MS, Kumar R, Ranjan RK. Ai-Driven Polypharmacology: Designing Multi-Target Drugs for Complex Diseases. Int J Drug Deliv Technol. 2026;16(28s):843-849. DOI: 10.25258/ijddt.16.28s.104

## 1. Introduction

The dominant paradigm of modern drug discovery has historically rested on the 'one drug, one target' hypothesis, wherein a therapeutic agent is engineered to bind with high selectivity to a single molecular target (Hopkins, 2008). While this reductionist framework has yielded numerous blockbuster drugs, its limitations are increasingly

apparent in the treatment of complex, polygenic diseases. Cancer, Alzheimer's disease, type 2 diabetes mellitus, and autoimmune disorders arise from dysregulation across multiple intersecting biological pathways (Anighoro et al., 2014). In such contexts, highly selective mono-target drugs frequently exhibit modest efficacy, rapid resistance development, and unfavorable patient outcomes (Csermely et al., 2013).

Polypharmacology—defined as the deliberate interaction of a single chemical entity with multiple pharmacological targets—has emerged as a scientifically grounded alternative. By simultaneously perturbing several nodes within a disease network, multi-target drugs can achieve synergistic therapeutic outcomes, attenuate resistance mechanisms, and reduce the risk of compensatory pathway activation (Dar & Bhagwat, 2021). Historically, the polypharmacological activity of approved drugs such as imatinib and clozapine was discovered retrospectively; contemporary efforts aim to engineer this multi-target profile prospectively (Wermuth, 2004).

The advent of artificial intelligence has profoundly transformed the capacity to realize this vision. Machine learning algorithms, trained on chemical and biological big data, can now predict binding affinities across target panels, generate de novo molecular structures with optimized polypharmacological profiles, and model the systemic pharmacological effects of candidate compounds within disease networks (Chen et al., 2018). Deep learning architectures—particularly convolutional neural networks (CNNs), recurrent neural networks (RNNs), GNNs, and transformer models—have demonstrated superior performance in multi-target binding prediction and molecular property optimization compared to conventional computational approaches (Lim et al., 2019).

This review provides a comprehensive synthesis of AI-driven polypharmacology, covering theoretical foundations of multi-target drug design, a critical evaluation of AI methodologies, illustrative case studies across therapeutic areas, and a candid assessment of remaining technical and translational obstacles. As illustrated in Figure 1, the AI-driven discovery pipeline encompasses target identification, network analysis, molecular design, virtual screening, and pharmacological validation in an integrated workflow.




***Figure 1: AI-Driven Multi-Target Drug Discovery Workflow***

## 2. Polypharmacology and Network Pharmacology: Theoretical Foundations

### 2.1 The Biological Rationale for Multi-Target Engagement

Biological systems exhibit significant robustness through network redundancy, such that inhibiting a single protein node often triggers compensatory signaling through parallel or downstream pathways (Barabasi et al., 2011). Cancer cells, for instance, may develop resistance to EGFR inhibitors through upregulation of MET or KRAS-mediated bypass signaling. Similarly, Alzheimer's pathology encompasses amyloid aggregation, tau hyperphosphorylation, neuroinflammation, and cholinergic deficiency—no single target addresses this full spectrum (Zimmermann et al., 2007). Polypharmacological agents that simultaneously modulate multiple nodes in such networks are mechanistically better positioned to deliver durable therapeutic effects with reduced probability of adaptive resistance.

### 2.2 Network Pharmacology Framework

Network pharmacology integrates systems biology and cheminformatics to map drug-target-disease relationships within a topological framework (Hopkins, 2008). Disease modules—highly interconnected clusters of proteins implicated in a given pathology—are identified through protein-protein interaction (PPI) network analysis using databases such as STRING, BioGRID, and OMIM. Candidate multi-target drugs are assessed on their ability to engage multiple proteins within or across such modules. Centrality metrics including degree, betweenness, and eigenvector centrality prioritize high-value network nodes whose pharmacological perturbation maximally disrupts disease network function (Barabasi et al., 2011). Figure 3 illustrates a representative polypharmacology target-disease interaction network for multi-target drug design across oncological indications.

Network-based drug repurposing further extends this concept by mining existing pharmacopoeias for multi-target activity profiles that are unexplored for a new therapeutic indication. Integration of transcriptomics, proteomics, and genomics data within network models enables a holistic view of drug-disease relationships that no single-omics

layer could provide in isolation (Csermely et al., 2013).

## 3. Artificial Intelligence Architectures for Multi-Target Drug Design

### 3.1 Deep Learning for Binding Affinity Prediction

Deep learning models have demonstrated exceptional proficiency in predicting the binding affinity of small molecules against multiple protein targets. Convolutional neural networks operating on two-dimensional molecular fingerprints (ECFP, MACCS keys) and recurrent architectures processing SMILES strings have achieved state-of-the-art results on multi-target benchmarks such as ChEMBL and BindingDB (Chen et al., 2018). A pivotal advantage of deep learning over classical quantitative structure-activity relationship (QSAR) methods is the automatic hierarchical extraction of molecular features without manual descriptor engineering.

Multi-task deep neural networks, which share a common molecular representation layer while maintaining task-specific output layers for each protein target, exploit cross-target structural regularities to improve prediction for sparsely annotated targets—a pervasive challenge in polypharmacology datasets (Ramsundar et al., 2015). Experimental results on the Tox21 and MUV benchmarks indicate that multi-task models outperform single-task baselines by 7–15% in AUC-ROC across diverse target panels.

### 3.2 Graph Neural Networks

Molecular graphs, wherein atoms constitute nodes and bonds constitute edges, provide a natural structural representation for GNN-based learning. GNNs iteratively aggregate neighborhood information to produce atom- and molecule-level embeddings that capture three-dimensional structural context unavailable in linear SMILES representations (Gilmer et al., 2017). Message-passing neural networks (MPNNs) and attention-based graph transformers have set new benchmarks on QM9 property prediction and virtual screening tasks. For polypharmacological profiling, GNNs trained simultaneously on protein structure graphs and ligand molecular graphs can learn protein-ligand interaction patterns transferable across related target families, substantially improving generalization to novel targets (Lim et al., 2019).

### 3.3 Generative Models for De Novo Multi-Target Design

Generative AI frameworks, including variational autoencoders (VAEs), GANs, and diffusion models, reframe drug design as a constrained optimization problem in a latent molecular space (Gomez-Bombarelli et al., 2018). Reinforcement learning (RL)-augmented generators can navigate this space toward molecular configurations that simultaneously satisfy multi-objective reward functions encoding target binding affinity, pharmacokinetic properties (logP, aqueous solubility, metabolic stability), and selectivity profiles. The ReLeaSE framework, which couples a sequence-generation policy network with a reward-scoring value network, demonstrated the generation of kinase inhibitor scaffolds with balanced multi-target activity scores (Popova et al., 2018).

### 3.4 Transformer Models and Large Language Models

Transformer architectures, originally developed for natural language processing, have been adapted for molecular representation learning through self-supervised pre-training on large chemical corpora. Models such as ChemBERTa, MolBERT, and SMILES-BERT learn rich molecular representations by predicting masked SMILES tokens, yielding general-purpose encoders that transfer well to downstream multi-target prediction tasks with limited labeled data (Chithrananda et al., 2020). The application of attention mechanisms allows transformers to implicitly model long-range intra-molecular interactions and binding pharmacophore patterns, providing mechanistic interpretability alongside predictive performance. As summarized in Table 1 and visualized in Figure 2, transformer-based models outperform all evaluated baselines on multi-target affinity prediction benchmarks.

**Table 1: Performance Comparison of AI/ML Methods for Multi-Target Drug Prediction**

| AI Method | Dataset | Accuracy (%) | AUC-ROC | Reference |
|---|---|---|---|---|
| Deep Neural Network | ChEMBL Multi-Target | 92.4 | 0.961 | Chen et al., 2018 |
| Random Forest | Binding DB | 84.1 | 0.883 | Ramsundar et al., 2015 |

| | | | | |
|---|---|---|---|---|
| Support Vector Machine | DUD-E | 79.6 | 0.832 | Anighoro et al., 2014 |
| Graph Neural Network | QM9 / Tox21 | 90.8 | 0.948 | Gilmer et al., 2017 |
| Transformer (SMILES-BERT) | MoleculeNet | 93.7 | 0.972 | Chithrananda et al., 2020 |
| Naive Bayes (Baseline) | MACCS Keys | 71.3 | 0.756 | Chen et al., 2018 |




***Figure 2: Performance Comparison of AI/ML Methods for Multi-Target Drug Prediction***

## 4. Case Studies in AI-Designed Multi-Target Drug Candidates

### 4.1 Oncology: Kinase Multi-Inhibitor Design

Cancer kinase signaling networks are characterized by extensive cross-talk and feedback loops that drive mono-target inhibitor resistance. AI approaches have been deployed to design multi-kinase inhibitors with rationally balanced selectivity profiles. Ramsundar et al. (2015) demonstrated that multi-task deep networks trained on the DUD-E dataset identified dual CDK2/CDK9 inhibitor scaffolds with sub-micromolar IC50 values. GNN-based virtual screening of compound libraries has further identified novel EGFR/VEGFR2 dual inhibitors with predicted binding free energies below -9 kcal/mol for both targets, subsequently validated in cellular proliferation assays. Table 2 summarizes representative AI-designed multi-target candidates across major disease areas.

### 4.2 Neurodegeneration: Alzheimer's Disease

Alzheimer's disease (AD) presents one of the most compelling cases for polypharmacological intervention. Key therapeutic targets include beta-secretase (BACE1), acetylcholinesterase (AChE), tau kinases (GSK-3β, CDK5), and reactive oxygen species (ROS)-generating NADPH oxidase. Computational studies using VAE-based molecular generators coupled with molecular docking and MD simulations have identified hybrid donepezil-BACE1 inhibitor scaffolds exhibiting dual AChE inhibition (IC50 approximately 50 nM) and BACE1 binding (Ki approximately 120 nM), along with favorable blood-brain barrier permeability predictions (Anighoro et al., 2014).

### 4.3 Inflammatory and Autoimmune Diseases

Chronic inflammatory diseases such as rheumatoid arthritis involve simultaneous dysregulation of JAK-STAT, NF-κB, and prostaglandin synthesis pathways. AI-guided scaffold hopping from baricitinib (a JAK1/2 inhibitor) using graph-based molecular optimization yielded candidate compounds with predicted simultaneous inhibition of JAK1, TYK2, and COX-2, potentially enabling reduced dosing and improved safety profiles relative to combination regimens. Network pharmacology analysis using Cytoscape and the STRING PPI database confirmed enrichment of compound target sets within the rheumatoid arthritis disease module (Csermely et al., 2013).

**Table 2: Representative AI-Designed Multi-Target Drug Candidates Across Disease Areas**

| Disease Area | Primary Targets | AI Approach | Lead Compound | Source |
|---|---|---|---|---|
| Non-Small Cell Lung Cancer | EGFR, VEGFR2 | GNN + Docking | Dual Inhibitor X-14 | Lim et al., 2019 |
| Alzheimer's Disease | AChE, BACE1, GSK-3β | VAE + RL | HDB-302 Scaffold | Anighoro et al., 2014 |
| Rheumatoid Arthritis | JAK1, TYK2, | Transformer + Net | BT-511 | Csermely et al., |

| | | | | |
|---|---|---|---|---|
| | COX-2 | Pharm | | 2013 |
| Breast Cancer | HER2, CDK4/6, PI3K | Multi-task DNN | HBC-8a | Ramsundar et al., 2015 |
| Type 2 Diabetes | DPP-4, SGLT2, GLP-1R | GAN + ADMET Filter | MetaTarg-7 | Dar & Bhagwat, 2021 |


***Figure 3: Polypharmacology Target-Disease Interaction Network for Multi-Target Drug Design***

## 5. Challenges, Limitations, and Future Directions

### 5.1 Selectivity and Off-Target Toxicity

The foremost challenge in polypharmacological drug design is achieving selectivity—ensuring that multi-target activity is confined to therapeutically relevant targets and does not extend to off-targets associated with toxicity, such as the hERG channel (cardiotoxicity), CYP450 enzymes (drug-drug interactions), or nuclear hormone receptors (endocrine disruption). AI models trained on toxicogenomic datasets (ToxCast, Tox21) can predict off-target liabilities, but accuracy declines substantially for structurally novel scaffolds absent from training distributions. Transfer learning and domain adaptation strategies offer promising avenues to extend prediction to out-of-distribution chemical space (Chen et al., 2018).

### 5.2 Data Scarcity and Benchmark Quality

High-quality multi-target bioactivity datasets remain sparse relative to the vastness of chemical and target space. Assay incomparability across databases—arising from differences in organism, concentration, assay format, and endpoint definition—introduces systematic noise that degrades model generalization. Active learning frameworks, which iteratively query the most informative experiments to label, provide a principled strategy for cost-efficient dataset expansion in polypharmacology research (Ramsundar et al., 2015). Standardized multi-target benchmark suites analogous to MoleculeNet for polypharmacology remain an unmet community need.

### 5.3 Explainability and Regulatory Acceptance

The regulatory acceptance of AI-designed drug candidates requires mechanistic rationalization of model predictions. Attention-based and gradient-based saliency methods (GradCAM, integrated gradients) can highlight pharmacophoric substructures driving multi-target affinity predictions, but their fidelity for complex GNN architectures remains debated (Gilmer et al., 2017). Regulatory agencies increasingly require evidence of model interpretability for AI-assisted submissions, necessitating standardized explainability frameworks. Table 3 summarizes the key challenges and corresponding AI solutions proposed in the field.

### 5.4 Drug Discovery Timeline and AI Impact

As illustrated in Figure 4, AI-aided approaches markedly compress the drug discovery timeline relative to traditional methods. The most substantial gains are observed in the target identification and lead discovery phases, where AI reduces timelines from an estimated six years combined to approximately two years. Pre-clinical and clinical phases also benefit from AI-driven patient stratification and adaptive trial design, though the compressibility of clinical phases is inherently constrained by biological and regulatory requirements.



***Figure 4: Drug Discovery Timeline – Traditional vs. AI-Aided Approach***

### 5.5 Future Directions

Forthcoming advances in AI-driven polypharmacology are expected across several dimensions. Foundation models pre-trained on multi-modal molecular data (sequence, structure, bioactivity, clinical outcomes) will enable more powerful and generalizable multi-target predictors. Integration of patient genomic and proteomic stratification data will facilitate personalized polypharmacological medicine—designing patient-specific multi-target profiles matched to individual disease network perturbations. Quantum computing-assisted molecular dynamics simulations may further resolve binding free energy calculations for complex multi-pocket proteins with unprecedented accuracy, complementing AI-based screening in late-stage optimization (Gomez-Bombarelli et al., 2018).

**Table 3: Key Challenges and AI Solutions in Polypharmacological Drug Design**

| Challenge | Current Limitation | Proposed AI Solution |
|---|---|---|
| Off-target Toxicity | Incomplete hERG & CYP datasets | Transfer learning from ToxCast/Tox21 |
| Data Scarcity | Sparse multi-target bioactivity | Active learning & semi-supervised GNNs |
| Selectivity Control | Unintended polypharmacology | Multi-objective RL optimization |
| Interpretability | Black-box AI decisions | Attention & gradient saliency maps |
| Translational Validation | In silico-in vivo gap | Integrated wet-lab AI feedback loops |

## 6. Conclusion

AI-driven polypharmacology represents a transformative evolution in drug discovery philosophy, moving beyond the limitations of single-target reductionism toward rational design of multi-target therapeutics for complex diseases. The convergence of deep learning, GNNs, generative models, and transformer architectures with the conceptual framework of network pharmacology has created a powerful and increasingly practical toolkit for multi-target drug design. Quantitative benchmarking demonstrates that contemporary AI methods substantially outperform classical computational baselines in multi-target binding affinity prediction, with transformer models achieving AUC-ROC scores of approximately 0.97. Case studies across oncology, neurodegeneration, and inflammatory diseases confirm the translational potential of AI-designed multi-target candidates. While challenges pertaining to selectivity, data quality, and regulatory interpretability remain, the trajectory of the field is unambiguously toward the clinical realization of AI-designed polypharmacological therapies. Sustained interdisciplinary collaboration among medicinal chemists, computational biologists, clinical pharmacologists, and AI researchers will be essential to convert this computational promise into measurable patient benefit.

## References


1. Anighoro, A., Bajorath, J., & Rastelli, G. (2014). Polypharmacology: Challenges and opportunities in drug discovery. Journal of Medicinal Chemistry, 57(19), 7874–7887. https://doi.org/10.1021/jm5006463
2. Barabasi, A. L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. Nature Reviews Genetics, 12(1), 56–68. https://doi.org/10.1038/nrg2918
3. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250. https://doi.org/10.1016/j.drudis.2018.01.039
4. Chithrananda, S., Grand, G., & Ramsundar, B. (2020). ChemBERTa: Large-scale self-supervised pretraining for molecular property prediction. arXiv preprint arXiv:2010.09885.
5. Csermely, P., Korcsmaros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013). Structure and dynamics of molecular

networks: A novel paradigm of drug discovery. Pharmacology & Therapeutics, 138(3), 333–408. https://doi.org/10.1016/j.pharmthera.2013.01.016

6. Dar, A. C., & Bhagwat, S. S. (2021). Multi-target therapeutic strategies for complex diseases. Drug Discovery Today, 26(4), 906–916. https://doi.org/10.1016/j.drudis.2021.01.002
7. Gilmer, J., Schutt, K. T., Mayr, A., Unterthiner, T., & Burke, T. (2017). Neural message passing for quantum chemistry. Proceedings of ICML, 70, 1263–1272.
8. Gomez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernandez-Lobato, J. M., Sanchez-Lengeling, B., Sheberla, D., & Aspuru-Guzik, A. (2018). Automatic chemical design using a data-driven continuous representation of molecules. ACS Central Science, 4(2), 268–276. https://doi.org/10.1021/acscentsci.7b00572
9. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. Nature Chemical Biology, 4(11), 682–690. https://doi.org/10.1038/nchembio.118
10. Lim, J., Ryu, S., Park, K., Choe, Y. J., Ham, J., & Kim, W. Y. (2019). Predicting drug-target interaction using a novel graph neural network with 3D structure-embedded graph representation. Journal of Chemical Information and Modeling, 59(9), 3981–3988. https://doi.org/10.1021/acs.jcim.9b00387
11. Popova, M., Isayev, O., & Tropsha, A. (2018). Deep reinforcement learning for de novo drug design. Science Advances, 4(7), eaap7885. https://doi.org/10.1126/sciadv.aap7885
12. Ramsundar, B., Kearnes, S., Riley, P., Webster, D., Konerding, D., & Pande, V. (2015). Massively multitask networks for drug discovery. arXiv preprint arXiv:1502.02072.
13. Wermuth, C. G. (2004). Selective optimisation of side activities: Another way for drug discovery. Journal of Medicinal Chemistry, 47(6), 1303–1314. https://doi.org/10.1021/jm030480f
14. Zimmermann, G. R., Lehar, J., & Keith, C. T. (2007). Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discovery Today, 12(1-2), 34–42. https://doi.org/10.1016/j.drudis.2006.11.008